迪法米拉斯特用于治疗亚托邦性皮肤炎
Egídio Freitas1, Tiago Torres1,2
1Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal.
The Journal of international medical research
|June 30, 2023
概括
迪法米拉斯特是一种新型局部固酶4抑制剂,在阿托皮性皮炎 (AD) 中提供快速的抗和抗炎作用. 临床试验表明,它在成人和儿童的长期治疗中是有效和耐受的.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亚托皮炎 (AD) 是一种普遍的慢性炎症性皮肤疾病,具有复杂的,不完全理解的发病因子.
- 目前的AD治疗方法在长期有效性和安全性方面存在局限性,需要新的局部疗法.
- 局部固酶4 (PDE4) 抑制剂代表了AD管理的有前途的治疗途径.
研究的目的:
- 综述目前关于局部PDE4抑制剂迪法米拉斯的文献,用于治疗亚托皮炎.
- 评估迪法米拉斯特在阿兹海默症治疗中的疗效,安全性和作用机制.
- 突出迪法米拉斯特作为阿尔茨海默病的长期治疗选择的潜力.
主要方法:
- 现有关于迪法米拉斯和亚托匹性皮肤炎的科学文献的叙述性综述.
- 分析了2期和3期临床试验的数据,这些临床试验涉及迪法米拉斯膏.
- 检查迪法米拉斯的药理性质,包括其化酶4抑制活性.
主要成果:
- 迪法米拉斯特表现出显著的抗和抗炎性质,具有快速起作用.
- 临床试验表明,迪法米拉斯膏在成人和儿科阿尔茨海默病患者中有效且耐受良好.
- 迪法米拉斯特于2021年在日本获得批准,作为第一个局部PDE4抑制剂,用于2岁及以上患者的AD治疗.
结论:
- 迪法米拉斯特 (Difamilast) 是一种新且有效的局部治疗选择,用于治疗亚托皮炎.
- 它有利的疗效和耐受性概况表明它适合长期治疗AD.
- 迪法米拉斯特通过提供一种新的作用机制来解决AD治疗的未满足需求.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
354
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
354
01:19Antiasthma Drugs: Leukotriene Modifiers
369
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
369
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
01:30Asthma-IV: Nursing Management
3.2K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.2K
01:24Cystic Fibrosis: Management
195
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
195